AzTrials
AzTrials

DexmedetomidinePhase 3NCT05158348

A Comparative Study to Measure the Effect of Nebulized Dexmedetomidine

A Phase 3 study testing Dexmedetomidine Hydrochloride, Nebulized lidocaine and Local infiltration of lidocaine in people with Dexmedetomidine and Lidocaine, run by Kasr El Aini Hospital at 1 site in Egypt.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

A comparative study to measure the effect of nebulized dexmedetomidine - lidocaine for controlling postoperative pain after tonsillectomy in adults. Read more about this study

Who is it for?
Ages 18 to 60 years
Conditions the study is for
Dexmedetomidine, Lidocaine, Tonsillectomy
What is being tested?
Dexmedetomidine Hydrochloride, Nebulized lidocaine and Local infiltration of lidocaine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
60 participants
Where
1 siteEgypt
Study dates
5 Nov 2021to 15 Apr 2022
Phase
Phase 3
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 60 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • Patients of either sex, aged between 18-30 years old, ASA physical status I, II undergoing tonsillectomy.

Who cannot join

  • Patients were excluded if they had clinically important coronary atherosclerotic heart disease, a history of stroke or transient ischemic attack, Sinus bradycardia or heart block, coagulopathy, peritonsillar abscess, any infection at the site of injection, Known allergy to the study drugs (lidocaine, dexmedetomidine).

Trial locations and contacts

1 site in 1 country.

Egypt1 site, 1 recruiting
  • Cairo university hospitals

    Cairo, 11559

    Dina Mohamad, MD, 01005249134, dinamahmoud@kasralainy.edu.eg

    Recruiting

Other trials in Egypt

About this study

Official title: A Comparative Study to Measure the Effect of Nebulized Dexmedetomidine - Lidocaine for Controlling Postoperative Pain After Tonsillectomy in Adults.

A comparative study to measure the effect of nebulized dexmedetomidine - lidocaine for controlling postoperative pain after tonsillectomy in adults.

Read the detailed description

Tonsillectomy is one of the most common procedures in ear, nose, and throat surgery. It is usually performed as a day-stay procedure. [1] Pain is the most common reason for physician contact after discharge, indicating that post-tonsillectomy pain is intense and undertreated. [2] Patients need analgesics that are effective and can be used safely at home.

Adults have a different pattern of pain compared with children; this is related to the different indications and techniques of tonsillectomy. [3, 4] In adults, the surgery is usually performed for chronic infection with scarred tonsils that requires dissection with coagulation, thus causing intense and longer-lasting pain. [5] In children, the indication is usually hypertrophy or recurrent acute infections with smaller changes in tonsil tissues than in adults. [6] Multimodal analgesia has become the standard of care in postoperative pain management. Combinations of analgesics with different sites or modes of action are commonly used to improve analgesia and to reduce the doses of individual analgesics (especially opioids) and to reduce adverse effects.

Systematic reviews on various analgesics for post-tonsillectomy pain have been published for paediatric and adolescent patients.(7,8) Paracetamol (alone and in combination with ibuprofen)NSAIDS,dexamethasone or gabapentenoids(9) Dexmedetomidine is a highly selective adrenergic α-2 agonist that does not cause respiratory depression and can be used as a sedative for various procedures. [10,11] Recently, the use of dexmedetomidine as an additive to local anaesthetics was reported to have several advantages over conventional intravenous administration. [12,13]

Nebulized dexmedetomidine combined with other anaesthetics as a premedication for outpatient paediatric dental procedures has also been reported to provide smoother induction of general anaesthesia with a more rapid recovery and no significant side effects. [14] Nebulized dexmedetomidine-lidocaine inhalation as a premedication for flexible bronchoscopy was well tolerated during bronchoscopies performed under moderate sedation and was associated with a reduced incidence of moderate to severe coughing, a shorter recovery time and reduced vasoconstrictor consumption(15).However, there are no data regarding the use of nebulized dexmedetomidine-lidocaine for controlling postoperative pain after tonsillectomy.

Comparative study II. Study setting and location This study will be conducted at Kasr Al-Ainy tertiary Hospital, Cairo University after being approved by the anesthesia department Research committee and obtaining written informed consent of patients III. Study population 60 patients undergoing tonsillectomy operation will be enrolled in this study divided into 3 groups each of 20 patients. Group A will receive intra-operative local infiltration of saline in tonsillar bed and post-operative nebulised dexametomidine and lidocaine. Group B will receive intra-operative local infiltration of saline and post-operative will receive nebulised lidocaine and group C will receive intra-operative local infiltration of lidocaine and post-operative nebulised saline.

IV. Eligibility Criteria

  1. Inclusion criteria Patients of either sex, aged between 18-50 years old, ASA physical status I, II undergoing tonsillectomy.
  2. Exclusion criteria Patients were excluded if they had clinically important coronary atherosclerotic heart disease, a history of stroke or transient ischemic attack, Sinus bradycardia or heart block, coagulopathy, peritonsillar abscess, any infection at the site of injection, Known allergy to the study drugs (lidocaine, dexmedetomidine).
  3. Study Procedures
  4. Randomization (in RCT only) All procedures will be performed by the same team, which include an ENT surgeon using the same technique in all study groups which is dissecting the tonsils by bipolar diathermy technique and surgeon will do the infiltration technique also and a specialized anaesthesiologist for the inhalational technique ,the patients will be informed about the procedure ,technique of the intra-operative and post-operative pain control and the VAS scoring system before the operation. Randomization and drug masking will be completed by a specialist who will not be directly involved in the trials. The patients will be divided into 3 groups; Group A will receive intra-operative local infiltration of saline in tonsillar bed and post-operative nebulised dexametomidine and lidocaine. Group B will receive intra-operative local infiltration of saline and post-operative will receive nebulised lidocaine and group C will receive intra-operative local infiltration of lidocaine and post-operative nebulised saline.

Study Protocol Upon arrival to the operating room, a pulse oximetry, capnography, continuous electrocardiogram (ECG), and non-invasive blood pressure measurement device will be connected to the patient. A large bore cannula will be inserted. Pre-medications will be given; Antiemetics as metclopromide(10mg) or dexamethasone(8mg) to decrease laryngeal edema postoperatively. Anesthesia will be induced with IV Propofol, 1.5 mg/kg and IV fentanyl 1 mic/kg and atracurium 0.5 mg/kg. Patients will be intubated and ventilated with oxygen maintaining ETCO2 at 35-40 mmHg. Anesthesia will be maintained with oxygen, isoflurane and atracurium providing muscle relaxation as a maintenance.

  • Group A will receive intra-operative local infiltration of saline in tonsillar bed by the surgeon and post-operative nebulised dexametomidine(0.6mic per kg) and lidocaine(1 mic per kg)by specialized anesthesiologist. Group B will receive intra-operative local infiltration of saline by the surgeon and post-operative will receive neublised lidocaine(1 mic per kg) by specialized anesthesiologist and group C will receive intra-operative local infiltration of lidocaine(1 mic per kg) in the tonsillar bed by the surgeon and post-operative nebulised saline by the anesthesiologist.
Being tested
Dexmedetomidine Hydrochloride, Nebulized lidocaine, Local infiltration of lidocaine
Keywords
Post tonsillectomy, Pain, Dexmedetomidine, Lidocaine
Medical subject headings
Pain

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Dexmedetomidine HydrochlorideDrug

    Group A will receive post-operative nebulised dexametomidine and lidocaine.

  • Nebulized lidocaineDrug

    Group B will receive post-operative will receive nebulised lidocaine

  • Local infiltration of lidocaineDrug

    group C will receive intra-operative local infiltration of lidocaine

Study groups in NCT05158348
Study groupRoleWhat they receive
Group AActive comparatorreceive intra-operative local infiltration of saline in tonsillar bed and post-operative nebulised dexametomidine and lidocaine.
Receives: Drug: Dexmedetomidine Hydrochloride
Group BActive comparatorreceive intra-operative local infiltration of saline and post-operative will receive nebulised lidocaine
Receives: Drug: Nebulized lidocaine
Group CActive comparatorreceive intra-operative local infiltration of lidocaine and post-operative nebulised saline.
Receives: Drug: Local infiltration of lidocaine

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Postoperative pain 4 hours after tonsillectomy measured by visual analogue score

    Measured: 4 hours postoperative

Secondary outcomes (1)
  1. Postoperative nausea and vomiting following tonsillectomy operation after1 hour , 2 hours and after 4 hours

    Measured: 4 hours postoperative

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Dec 2021
  2. Study start5 Nov 2021
  3. Primary completion10 Apr 2022 (estimated)
  4. Study completion15 Apr 2022 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
60 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05158348
Sponsor's protocol ID
MS-394-2020
Status last verified
Dec 2021
First submitted
7 Dec 2021
Last updated
15 Dec 2021
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Dexmedetomidine Hydrochloride, Nebulized lidocaine and Local infiltration of lidocaine in people with Dexmedetomidine and Lidocaine, run by Kasr El Aini Hospital at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 15 Dec 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Dina Mohamed (01005249134, dinamahmoud@kasralainy.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Postoperative pain 4 hours after tonsillectomy measured by visual analogue score (time frame: 4 hours postoperative). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Dec 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in